Artelon, Inc. Secures $20M in Funding to Advance Surgical Treatment of Joint Instability

New financing led by Vensana Capital to support commercial expansion and launch of new surgical solutions for joint instability

Summation

  •   “Following on the commercial success of our current Flexband® SOLO and Flexband MULTI products, this funding will allow us to take on adjacent clinical indications and pursue leadership within the $2B U.
  • It has been proven in clinical studies to protect the surgical repair during early healing, quickly restore the mechanics of motion, and support development of regenerating tissue before dissolving over five to six years.
  • ”  Added Vensana's Kirk Nielsen, “Vensana is excited to join the Artelon team and to support their efforts to establish themselves as a technology and market leader.

Artelon Inc., a privately held medical device company, announced today that it closed approximately $20 million in Series B funding, led by Vensana Capital with expected additional participation from existing investors. The financing will fund commercial growth, clinical research, and expansion of Artelon’s product line for surgical treatment of ankles and other joints.

“Artelon has focused deeply on surgical solutions for ankle instability, a large and underserved market” said CEO Aaron Smith.  “Ankle sprains are the number one reason for emergency room visits in the United States, and up to 20 percent of those patients will develop chronic instability after these injuries.  While traditional surgical procedures can mitigate ankle instability, patients endure a long recovery period and can still have residual pain or instability over the long term.”  Artelon’s innovative surgical solutions represent more than 30 years of research and expertise on the complex interaction of mechanics and biology in tendon and ligament reconstruction.  “Following on the commercial success of our current Flexband® SOLO and Flexband MULTI products, this funding will allow us to take on adjacent clinical indications and pursue leadership within the $2B U.S. ankle instability market, while expanding our efforts to address latent customer needs in other unstable joints.”

Artelon is focused on bringing value to patients and healthcare providers through a platform that enhances soft tissue repair while restoring stability and motion,” said Greg Banker of Vensana Capital.  “They are on a mission to enable faster recovery and improved outcomes for patients, while fitting seamlessly into clinical workflows.”  Added Vensana’s Kirk Nielsen, “Vensana is excited to join the Artelon team and to support their efforts to establish themselves as a technology and market leader.”

Artelon’s Dynamic Matrix™ technology is a proprietary polymeric bio-textile for musculoskeletal soft tissue reconstruction.  Dynamic Matrix is designed to mimic the natural mechanical and biological properties of healing ligament tissue. It has been proven in clinical studies to protect the surgical repair during early healing, quickly restore the mechanics of motion, and support development of regenerating tissue before dissolving over five to six years.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

Funding will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations reports Phenomix Sciences.

R3 Vascular Announces $87 Million in Series B Financing

R3 Vascular will use the proceeds to support the ELITE FDA IDE pivotal trial of its best-in-class bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD. 

Nami Surgical Secures Investment to Transform Robotic-Assisted Surgery Market

Nami Surgical develops miniaturised ultrasonic medical devices for surgical applications, and supports medical device companies to deliver innovation in ultrasonic surgery. In a groundbreaking development, Nami has introduced a high-performance, miniaturised ultrasonic scalpel, overcoming significant barriers in robotic-assisted surgery. Traditionally favoured in laparoscopic procedures, ultrasonic scalpels have been too large for effective use in robotic surgery until now.

By using this website you agree to accept Medical Device News Magazine Privacy Policy